Home
GLUE
GLUE News

Latest Monte Rosa Therapeutics Inc. (GLUE) News on August 23, 2025

MT Newswires

2 months ago

Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

GlobeNewswire

2 months ago

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

Zacks

2 months ago

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire

3 months ago

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

Zacks

4 months ago

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

Associated Press Finance

4 months ago

Monte Rosa Therapeutics: Q1 Earnings Snapshot

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics Insider Ups Holding During Year

Simply Wall St.

4 months ago

Monte Rosa Therapeutics Insider Ups Holding During Year

Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect

GuruFocus.com

5 months ago

Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect

Mixed data results for two Monte Rosa molecular glue degraders

Clinical Trials Arena

5 months ago

Mixed data results for two Monte Rosa molecular glue degraders

MT Newswires

5 months ago

Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

Zacks

5 months ago

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

MT Newswires

5 months ago

Monte Rosa Therapeutics Files $400 Million Mixed Shelf

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

GlobeNewswire

5 months ago

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GlobeNewswire

5 months ago

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

3 Top Cancer Biotechs to Keep An Eye On in 2025

Zacks

6 months ago

3 Top Cancer Biotechs to Keep An Eye On in 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

6 months ago

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

7 months ago

Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans

Monte Rosa Therapeutics provide corporate update, key milestones 2025

TipRanks

7 months ago

Monte Rosa Therapeutics provide corporate update, key milestones 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

8 months ago

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

8 months ago

Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

GlobeNewswire

8 months ago

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

MT Newswires

8 months ago

Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression

MT Newswires

8 months ago

Monte Rosa Closes Global License Agreement With Novartis

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

GlobeNewswire

8 months ago

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire

8 months ago

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study

TipRanks

9 months ago

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

GlobeNewswire

9 months ago

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

Zacks

9 months ago

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire

9 months ago

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet

Zacks

9 months ago

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire

9 months ago

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),

Simply Wall St.

9 months ago

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

10 months ago

Monte Rosa Therapeutics: Q3 Earnings Snapshot

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

10 months ago

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice

Zacks

10 months ago

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade

Zacks

10 months ago

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

TipRanks

10 months ago

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis

GuruFocus.com

10 months ago

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

Investor's Business Daily

10 months ago

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

MT Newswires

10 months ago

Top Midday Gainers

This Biotech Stock Has Doubled Its Value Today—Here's Why

Investopedia

10 months ago

This Biotech Stock Has Doubled Its Value Today—Here's Why

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

Investor's Business Daily

10 months ago

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

MT Newswires

10 months ago

Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Reuters

10 months ago

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

Benzinga

10 months ago

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

MT Newswires

10 months ago

Monte Rosa Therapeutics Enters Global License Deal With Novartis; Shares Jump Pre-Bell

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

BioPharma Dive

10 months ago

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire

10 months ago

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

GlobeNewswire

10 months ago

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 09/25/2024

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

MT Newswires

a year ago

Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

a year ago

Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

GlobeNewswire

a year ago

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

GlobeNewswire

a year ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

GlobeNewswire

a year ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Simply Wall St.

a year ago

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

MT Newswires

a year ago

Monte Rosa Therapeutics Names Three Insiders to Leadership Team

Monte Rosa Therapeutics Announces Leadership Team Promotions

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Leadership Team Promotions

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

GlobeNewswire

a year ago

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

MT Newswires

a year ago

Monte Rosa Therapeutics Prices $100 Million Public Offering

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GuruFocus.com

a year ago

Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Associated Press Finance

a year ago

Monte Rosa Therapeutics: Q1 Earnings Snapshot

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

MT Newswires

a year ago

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Zacks

a year ago

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Zacks

a year ago

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

Zacks

a year ago

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

GuruFocus.com

a year ago

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Simply Wall St.

a year ago

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Associated Press Finance

a year ago

Monte Rosa Therapeutics: Q4 Earnings Snapshot

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Unitil Increases Common Stock Dividend

GlobeNewswire

2 years ago

Unitil Increases Common Stock Dividend

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Zacks

2 years ago

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Sierra Bancorp (BSRR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

2 years ago

Sierra Bancorp (BSRR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Despite Fast-paced Momentum, Carrols Restaurant (TAST) Is Still a Bargain Stock

Zacks

2 years ago

Despite Fast-paced Momentum, Carrols Restaurant (TAST) Is Still a Bargain Stock

Southside Bancshares, Inc. (NASDAQ:SBSI) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Southside Bancshares, Inc. (NASDAQ:SBSI) Q4 2023 Earnings Call Transcript

Share on Social Networks: